LCE1B Inhibitors
LCE1B Inhibitors are a range of chemical compounds that impede the functional activity of LCE1B by targeting specific signaling pathways that LCE1B is part of, particularly those involving protein kinase C (PKC). Staurosporine serves as a broad-spectrum kinase inhibitor that, by hampering PKC activity, indirectly leads to a reduction in LCE1B function. Similarly, Chelerythrine and Sphingosine focus on inhibiting PKC, resulting in a downscale of LCE1B activity. Bisindolylmaleimide I, with its selective PKC inhibition, and Calphostin C, another potent PKC blocker, also contribute to the decline in LCE1B's operational capabilities. Moreover, Gö 6983 and Gö 6976, both targeting PKC isoforms, along with Ro 31-8220, are instrumentalin diminishing the activity of LCE1B by altering the upstream PKC-mediated signaling events. The same holds true for Sotrastaurin, which by inhibiting PKC, ultimately diminishes LCE1B activity.
Further narrowing down the spectrum of PKC inhibition, Enzastaurin and LY-333,531 specifically target PKCβ, a kinase that plays a significant role in modulating LCE1B. Their inhibition of PKCβ results in a less active LCE1B, demonstrating the precise control of LCE1B activity through PKCβ-dependent pathways. Hispidin rounds out this array of inhibitors with its dual-action as a PKC inhibitor and antioxidant, further establishing the critical relationship between PKC activity and LCE1B functionality. Collectively, these LCE1B Inhibitors exemplify a targeted approach to diminishing the functional activity of LCE1B through a concerted blockade of PKC-related signaling, which is essential for the proper modulation of LCE1B within its biological context.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a potent protein kinase inhibitor, can inhibit a broad spectrum of kinases. By inhibiting protein kinase C (PKC), it indirectly diminishes the activity of LCE1B, which is influenced by PKC-mediated signaling. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Chelerythrine is a specific inhibitor of protein kinase C. By blocking PKC activity, it can lead to reduced function of LCE1B, which is modulated through PKC-dependent pathways. | ||||||
D-erythro-Sphingosine | 123-78-4 | sc-3546 sc-3546A sc-3546B sc-3546C sc-3546D sc-3546E | 10 mg 25 mg 100 mg 1 g 5 g 10 g | $90.00 $194.00 $510.00 $2448.00 $9384.00 $15300.00 | 2 | |
Sphingosine serves as an inhibitor of protein kinase C. By diminishing PKC activity, sphingosine indirectly lowers the functional activity of LCE1B, which is regulated in part by PKC signaling pathways. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a selective inhibitor of PKC. It reduces LCE1B activity by inhibiting PKC, which is a kinase that influences LCE1B through various signaling events. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $343.00 $1642.00 | 20 | |
Calphostin C, a potent inhibitor of PKC, indirectly decreases the functional activity of LCE1B by targeting PKC which is involved in the modulation of LCE1B-related signaling. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 acts as a pan-PKC inhibitor. By inhibiting various isoforms of PKC, it indirectly leads to the diminished functionality of LCE1B, as PKC pathways can modulate LCE1B activity. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö 6976 selectively inhibits certain PKC isoforms. Its inhibition of PKC leads to reduced activity of LCE1B by affecting the PKC-mediated signaling events that LCE1B is involved in. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro 31-8220 functions as a PKC inhibitor. By inhibiting PKC activity, it may lead to the indirect decrease of LCE1B function, since LCE1B is modulated by PKC-dependent signaling pathways. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin is known to inhibit PKC. Its inhibition of PKC activity contributes to a decrease in LCE1B functional activity, as LCE1B is thought to be influenced by PKC signaling. | ||||||
Enzastaurin | 170364-57-5 | sc-364488 sc-364488A sc-364488B | 10 mg 50 mg 200 mg | $259.00 $612.00 $1721.00 | 3 | |
Enzastaurin, a PKCβ inhibitor, reduces the signaling mediated by PKCβ. Since PKCβ can regulate the activity of LCE1B, the inhibition of PKCβ by enzastaurin leads to a decrease in LCE1B function. | ||||||